InvestorsHub Logo
Followers 0
Posts 3
Boards Moderated 0
Alias Born 07/25/2010

Re: None

Wednesday, 01/08/2014 9:57:25 AM

Wednesday, January 08, 2014 9:57:25 AM

Post# of 724
Path "skyrocketed 36% in pre-market trading on Wednesday as the company has received an acquisition offer from Israel’s Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) for $114 million plus milestone payments related to NuPathe’s Zecuity migraine treatment. The offer of $3.65 per share has been made less than a month after U.S. specialty pharmaceutical company Endo Health Solutions Inc (ENDP) said it would acquire NuPathe for about $105 million, or $2.85 per share. The new bid represents a premium of 13 percent to NuPathe shares’ Tuesday close, excluding milestone payments."


http://www.istreetwire.com/stocks-rallying-on-good-news-nupathe-inc-path-catalyst-pharmaceutical-cprx-biomarin-bmrn-oclaro-inc-oclr-teva-pharmaceutical-industries-teva/143119/

Tom
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PATH News